{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:58:06Z","timestamp":1792627086344,"version":"4.5.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immunotherapy with checkpoint inhibitors is an efficient treatment for metastatic melanoma. Development of vitiligo upon immunotherapy represents a specific immune-related adverse event (irAE) diagnosed in 15% of patients and associated with a positive clinical response. Therefore, a detailed characterization of immune cells during vitiligo onset in melanoma patients would give insight into the immune mechanisms mediating both the irAE and the anti-tumor response. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To better understand these aspects, we analyzed T cell subsets from peripheral blood of metastatic melanoma patients undergoing treatment with anti-programmed cell death protein (PD)-1 antibodies. To deeply characterize the antitumoral T cell response concomitant to vitiligo onset, we analyzed T cell content in skin biopsies collected from melanoma patients who developed vitiligo. Moreover, to further characterize T cells in vitiligo skin lesion of melanoma patients, we sequenced T cell receptor (TCR) of cells derived from biopsies of vitiligo and primary melanoma of the same patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion<\/jats:title><jats:p>Stratification of patients for developing or not developing vitiligo during anti-PD-1 therapy revealed an association between blood reduction of CD8-mucosal associated invariant T (MAIT), T helper (h) 17, natural killer (NK) CD56<jats:sup>bright<\/jats:sup>, and T regulatory (T-reg) cells and vitiligo onset. Consistently with the observed blood reduction of Th17 cells in melanoma patients developing vitiligo during immunotherapy, we found high amount of IL-17A expressing cells in the vitiligo skin biopsy, suggesting a possible migration of Th17 cells from the blood into the autoimmune lesion. Interestingly, except for a few cases, we found different TCR sequences between vitiligo and primary melanoma lesions. In contrast, shared TCR sequences were identified between vitiligo and metastatic tissues of the same patient. These data indicate that T cell response against normal melanocytes, which is involved in vitiligo onset, is not typically mediated by reactivation of specific T cell clones infiltrating primary melanoma but may be elicited by T cell clones targeting metastatic tissues. Altogether, our data indicate that anti-PD-1 therapy induces a de novo immune response, stimulated by the presence of metastatic cells, and composed of different T cell subtypes, which may trigger the development of vitiligo and the response against metastatic tumor.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1197630","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:28:46Z","timestamp":1692818926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Maria Luigia","family":"Carbone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Guercio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Alessandro","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Ramondino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Quintarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Maria","family":"Failla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/9525","article-title":"Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients","volume":"5","author":"Lee","year":"1999","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.07.006","article-title":"Metastatic melanoma and immunotherapy","volume":"172","author":"Herzberg","year":"2016","journal-title":"Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.3390\/ijms20225731","article-title":"Melanoma and vitiligo: in good company","volume":"20","author":"Failla","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.21203\/rs.3.rs-827134\/v1","article-title":"Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients","volume":"148","author":"Verkhovskaia","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1999.00805.x","article-title":"Accumulation of identical T cells in melanoma and vitiligo-like leukoderma","volume":"113","author":"Becker","year":"1999","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-019-0533-0","article-title":"Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors","volume":"7","author":"Rapisuwon","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.821598","article-title":"Cancer and Autoimmune diseases: a tale of two immunological opposites","volume":"13","author":"Elkoshi","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41571-021-00508-x","article-title":"Beneficial autoimmunity improves cancer prognosis","volume":"18","author":"Zitvogel","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5448","DOI":"10.1038\/s41598-022-09373-9","article-title":"Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients","volume":"12","author":"Carbone","year":"2022","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: american joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-019-0281-x","article-title":"iRECIST: how to do it","volume":"20","author":"Persigehl","year":"2020","journal-title":"Cancer Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1812273115","article-title":"The CD4(-)CD8(-) MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8(+) MAIT cell pool","volume":"115","author":"Dias","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.890298","article-title":"Proinflammatory mucosal-associated invariant CD8+ T cells react to gut flora yeasts and infiltrate multiple sclerosis brain","volume":"13","author":"Gargano","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ni1467","article-title":"Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-0716-1311-5_2","article-title":"Identification and purification of human memory T helper cells from peripheral blood","volume":"2285","author":"Capone","year":"2021","journal-title":"Methods Mol Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217604","article-title":"Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells","volume":"114","author":"Robins","year":"2009","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1038\/ncomms3680","article-title":"Using synthetic templates to design an unbiased multiplex PCR assay","volume":"4","author":"Carlson","year":"2013","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2011.09.001","article-title":"Ultra-sensitive detection of rare T cell clones","volume":"375","author":"Robins","year":"2012","journal-title":"J Immunol Methods"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bth945","article-title":"IMGT\/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs","author":"Yousfi Monod","year":"2004","journal-title":"Bioinformatics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/path.4260","article-title":"High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer","volume":"231","author":"Emerson","year":"2013","journal-title":"J Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"134ra63","DOI":"10.1126\/scitranslmed.3003656","article-title":"High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia","volume":"4","author":"Wu","year":"2012","journal-title":"Sci Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008694","article-title":"Mapping change in large networks","volume":"5","author":"Rosvall","year":"2010","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00178","article-title":"Melanoma immunotherapy: next-generation biomarkers","volume":"8","author":"Hogan","year":"2018","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1204507","article-title":"Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma","volume":"5","author":"Inoue","year":"2016","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0154","article-title":"Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma","volume":"2","author":"Bajor","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xcrm.2020.100141","article-title":"Combined TCR repertoire profiles and blood cell phenotypes predict melanoma patient response to personalized neoantigen therapy plus anti-PD-1","volume":"1","author":"Poran","year":"2020","journal-title":"Cell Rep Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/biomedicines10071639","article-title":"Current concepts of vitiligo immunopathogenesis","volume":"10","author":"Hla\u010da","year":"2022","journal-title":"Biomedicines"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646723","article-title":"IL-17 and IL-22 in immunity: driving protection and pathology","volume":"47","author":"Eyerich","year":"2017","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: a review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018907","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01014","article-title":"MAIT cell activation and functions","volume":"11","author":"Hinks","year":"2020","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01015-y","article-title":"Markers and makers of NKT17 cells","volume":"55","author":"Liman","year":"2023","journal-title":"Exp Mol Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/imr.12918","article-title":"From thymus to periphery: Molecular basis of effector \u03b3\u03b4-T cell differentiation","volume":"298","author":"Fiala","year":"2020","journal-title":"Immunol Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/cancers15020329","article-title":"A subset of PD-1-expressing CD56(bright) NK cells identifies patients with good response to immune checkpoint inhibitors in lung cancer","volume":"15","author":"Gasc\u00f3n-Ruiz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.9940","article-title":"Tumor infiltrating lymphocytes: the regulator of melanoma evolution","volume":"17","author":"Antohe","year":"2019","journal-title":"Oncol Lett"},{"key":"B46","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1197630\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:28:48Z","timestamp":1692818928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1197630\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2023.1197630"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1197630","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"article-number":"1197630"}}